Company research / CTOR
Citius Oncology, Inc. (CTOR)
- Sector Manufacturing
- Incorporated DE
- Fiscal year ends around Sep 30
Key ratios (year ended 2025-09-30)
-55.2%
Return on year-end equity
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $3.39M | $6.42M | $4.93M | n/a | $4.24M | n/a | n/a |
| Operating Income | -$47.29M | -$23.52M | -$20.57M | n/a | n/a | -$138.1K | n/a |
| Net Income | -$46.06M | -$24.76M | -$21.15M | n/a | -$12.70M | n/a | n/a |
| EPS (Diluted) | n/a | -$0.34 | -$0.31 | n/a | -$0.19 | n/a | n/a |
| Total Assets | $112.09M | $100.94M | $84.37M | $72.62M | $47.73M | $68.19M | $126.4K |
| Total Liabilities | $71.71M | $56.08M | $38.23M | n/a | $22.20M | n/a | n/a |
| Shareholders' Equity | $40.38M | $44.87M | $46.14M | -$1.99M | $25.54M | $345.5K | -$10.1K |
| Operating Cash Flow | n/a | -$5.49M | $126.4K | n/a | n/a | -$48.0K | n/a |
| Shares Outstanding | 105.76M | 83.51M | 71.55M | 2.34M | 67.50M | 2.42M | 2.42M |
| Weighted Average Diluted Shares | n/a | 73.27M | 68.05M | n/a | 67.50M | n/a | n/a |
| EPS (Basic) | n/a | -$0.34 | -$0.31 | n/a | -$0.19 | n/a | n/a |